Eflornithine
- Generic Name
- Eflornithine
- Brand Names
- Vaniqa
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12F2N2O2
- CAS Number
- 70052-12-9
- Unique Ingredient Identifier
- ZQN1G5V6SR
- Background
Eflornithine is a prescription drug indicated in the treatment of facial hirsutism (excessive hair growth). Eflornithine hydrochloride cream for topical application is intended for use in women suffering from facial hirsutism and is sold by Allergan, Inc. under the brand name Vaniqa. Eflornithine for injection against sleeping sickness was manufactured by Sa...
- Indication
Eflornithine is indicated in the treatment of facial hirsutism (excessive hair growth).
- Associated Conditions
- Meningoencephalitic stage Trypanosoma brucei gambiense infection
- Associated Therapies
- Hair removal therapy
Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
- First Posted Date
- 2014-05-15
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 16
- Registration Number
- NCT02139397
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 30
- Registration Number
- NCT02030964
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇦🇺Sydney Childrens Hospital KCC, Randwick, Australia
🇺🇸Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 394
- Registration Number
- NCT01685827
- Locations
- 🇨🇬
CRT (Centre de Réference et de Traitement) Dipumba, Dipumba general hospital, Mbuji Mayi, East Kasai, Congo
🇨🇬HGR ISANGI hospital, Isangi, Province Orientale, Congo
🇨🇬Masi Manimba Hospital, Masi Manimba, Bandundu - DRC, Congo
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
- Conditions
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT01483144
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 21
- Registration Number
- NCT01059071
- Locations
- 🇺🇸
Connecticut Children's Hospital, Hartford, Connecticut, United States
🇺🇸Levine Children's Hospital, Charlotte, North Carolina, United States
🇺🇸UVM/FAHC, Burlington, Vermont, United States
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT00983580
- Locations
- 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Efficacy - Safety of Eflornithine-Nifurtimox Combination Versus Eflornithine to Treat Human African Trypanosomiasis
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 280
- Registration Number
- NCT00146627
- Locations
- 🇨🇩
MSF-Belgium; PNLTHA, Epicentre, Isangi, Congo, The Democratic Republic of the
🇨🇩PNLTHA, STI, Epicentre, Mbuyi Maji, Congo, The Democratic Republic of the
🇨🇬MSF-Holland, Nkayi, RoC, Congo
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
- Conditions
- Interventions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 375
- Registration Number
- NCT00118365
- Locations
- 🇺🇸
University of California Medical Center At Irvine-Orange Campus, Orange, California, United States
Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT00005884
Neoadjuvant Eflornithine and Bicalutamide Compared With Eflornithine Alone, Bicalutamide Alone, and No Neoadjuvant Therapy in Treating Patients With Localized Prostate Cancer Undergoing Brachytherapy or Radical Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2004-07-12
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 34
- Registration Number
- NCT00086736
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.